Advanced Search

 

Study ID Status Title Patient Level Data
SAS10002 Completed A Four-Period Crossover, Placebo Controlled Study to Investigate the Pharmacokinetic and Pharmacodynamic Effects of Salmeterol/Fluticasone Propionate/HFA134A via MDI in Combination Compared With Salmeterol/P11/12 and Fluticasone Propionate/P11/12 via MDI Administered Individually.
SAS10003 Completed A Double-Blind, Placebo-Controlled Four Way Crossover Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Fluticasone Propionate and Salmeterol With Increasing Dose Strengths of the Fluticasone Propionate/Salmeterol/HFA134A MDI Combination Product
SAS10005 Completed A part-randomized, single-blind, placebo-controlled, five-way crossover study to assess the absolute bioavailability, relative bioavailability and comparative pharmacodynamics of fluticasone propionate from ADVAIR HFA MDI, ADVAIR DISKUS, FP CFC MDI and intravenous FP and to assess the relative b ...
SAS10006 Completed A 12-week, randomized, double-blind, placebo-controlled, 3-way crossover study in adult subjects with asthma aged 18-55 years to examine the pharmacodynamics and pharmacokinetics of fluticasone propionate (FP) administered twice daily via the Diskus (FP 100mcg) and the FP/Salmeterol (SALM) combination product (FP 100mcg/SALM 50mcg) administered twice daily via the Diskus Study Listed on ClinicalStudyDataRequest.com
SAS10007 Completed A 16-week, randomized, double-blind, double-dummy, placebo-controlled, 4-way crossover study in adult subjects with asthma aged 18-55 years to examine the pharmacodynamics and pharmacokinetics of fluticasone propionate and salmeterol administered via FP/Salmeterol (SALM) combination product Diskus (FP 250mcg/SALM 50mcg), FP/Salmeterol combination metered dose inhaler (MDI) (FP 110mcg/SALM 21mcg) containing the hydrofluoroalkane (HFA) propellant, GR106642X, and FP MDI (FP 110mcg) containing HFA propellant Study Listed on ClinicalStudyDataRequest.com
SAS10013 Completed An open, parallel group, repeat dose study to determine the pharmacokinetics (PK) and pharmacodynamics (PD) of salmeterol and fluticasone propionate delivered as SERETIDE DISKUS (50/250mcg twice daily [b.i.d.]) in Japanese and Caucasian asthmatic subjects. Study Listed on ClinicalStudyDataRequest.com
SAS10014 Completed A study to compare the systemic pharmacodynamic effects and pharmacokinetics of SERETIDE DISKUS/ACCUHALER Inhaler (200/1000mcg) with salmeterol alone (200mcg) and fluticasone propionate alone (1000mcg) in healthy Japanese subjects Study Listed on ClinicalStudyDataRequest.com
SAS10015 Completed A randomised, double-blind, double-dummy, cross-over comparison of the salmeterol/fluticasone propionate combination product (50/250mg strength) twice daily via one Diskus inhaler with salmeterol 50mg twice daily via one Diskus inhaler plus fluticasone propionate 250mg twice daily via a second Diskus inhaler in Japanese and Caucasian asthmatics Study Listed on ClinicalStudyDataRequest.com
SAS10016 Completed A 4-week, randomized, double-blind, placebo run-in, parallel-group study in pediatric subjects with asthma aged 4-11 years to examine the pharmacodynamics and pharmacokinetics of the fluticasone propionate (FP) and salmeterol (SALM) combination product administered twice daily via the Diskus (FP 100mcg/SALM 50mcg) and the FP Diskus (FP 100mcg) Study Listed on ClinicalStudyDataRequest.com
SAS10017 Completed Randomized, Open-Label, Single-Dose, 4-Way Crossover Study to Compare the Relative Bioavailability and Pharmacodymanics of Fluticasone Propionate from Two Batches of Seretide MDI with Different in vitro Characteristics Study Listed on ClinicalStudyDataRequest.com
SAS10019 Completed A repeat dose, randomised, double blind, 2-way crossover study to assess the safety and systemic exposure of an investigational formulation compared to concurrent administration of individual Fluticasone Propionate 50 and Salmeterol 50 DISKUS inhalers in subjects aged 18 - 55 years with mild asthma Study Listed on ClinicalStudyDataRequest.com
SAS10020 Completed A single dose, randomized, double-blind, 2-way crossover study to assess the safety, tolerability, pharmacodynamics and pharmacokinetic profile of SERETIDE™ 50/50 compared to concurrent administration of individual FP 50 and SALM 50 inhalers in healthy subjects aged 18 – 55 years. Study Listed on ClinicalStudyDataRequest.com
SAS104449 Completed A randomised, open label, five-way crossover study to assess the systemic exposure of fluticasone propionate and salmeterol from SERETIDE/ADVAIR 250HFA MDI alone and with AeroChamber-Max spacer and VOLUMATIC both in their washed and unwashed states in adult subjects with mild or intermittent asthma Study Listed on ClinicalStudyDataRequest.com
SAS105519 Completed A repeat-dose, open-label, randomized, incomplete block design in pediatric subjects with asthma, ages 4 - 11 years, to compare systemic exposure and pharmacodynamics of fluticasone propionate and salmeterol following Advair HFA 45/21mcg (2 inhalations), ADVAIR® HFA 45/21mcg (2 inhalations) with Aerochamber Plus Spacer and Advair Diskus 100/50 twice daily Study Listed on ClinicalStudyDataRequest.com
SAS107541 Completed A long term follow up study for a comparison of stepwise treatment of asthmatic children with Salmeterol/Fluticasone propionate combination product (SERETIDE®) and/or Fluticasone propionate (FLIXOTIDE (TM)) based on PD20 methacholine and symptoms or based on symptoms only.
SAS20008 Completed A 12 week open study to assess the efficacy and safety of Seretide Diskus 50/250mcg, 1 inhalation twice daily in patients with reversible airway obstruction compatible with the diagnosis of asthma.
SAS30001 Completed A Randomized, Double-Blind, Active-Controlled, Parallel-Group, 12-Week Trial Evaluating the Safety and Efficacy of the Salmeterol/Fluticasone Propionate Combination in HFA 134a MDI, 42/88mcg BID, and Salmeterol in Propellant 11/12 MDI, 42mcg BID, and Fluticasone Propionate in Propellant 11/12 MD ...
SAS30003 Completed A Stratified, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 12-Week Trial Evaluating the Safety and Efficacy of the Salmeterol/Fluticasone Propionate Combination in HFA 134a MDI, 42/88mcg BID, and Salmeterol in Propellant 11/12 MDI, 42mcg BID, Fluticasone Propionate in Propellant ...
SAS30004 Completed A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group 12-Week Trial Evaluating the Safety and Efficacy of the Salmeterol/Fluticasone Propionate Combination...
SAS30005 Completed A 12-Month, Open-Label, Stratified Study to Assess the Long-Term Safety of Salmeterol/Fluticasone Propionate/HFA134a Inhalation Aerosol at Doses of 50/100mcg, 50/250mcg, and 50/500mcg BID in Adolescent and Adult Subjects with Asthma
SAS30013 Completed A study to compare the long term effects on airway inflammation of Seretide versus Flixotide in adult subjects with asthma.
SAS30014 Completed A single-centre, double-blind, randomised, cross-over study to compare the short term effects on airway inflammation after allergen challenge of salmeterol/fluticasone propionate combination product (Seretide) versus fluticasone propionate (Flixotide) in adult subjects with asthma.
SAS30015 Completed A phase IIIB, multi-centre, double-blind, parallel group, randomised study to compare the efficacy of the salmeterol/fluticasone propionate combination (25/50 mcg strength), 2 inhalations bd via HFA-MDI with beclomethasone dipropionate (BDP) 200mcg bd via metered...
SAS30017 Completed A Randomized, Double-Blind, Active-Controlled, Parallel-Group 12-Week Trial Evaluating the Safety and Efficacy of the 50/100mcg Salmeterol/Fluticasone Propionate DISKUS Combination Product twice daily Compared with Salmeterol 50mcg via DISKUS twice daily and Fluticasone Propionate 100mcg via DISKUS twice daily in Adult and Adolescent Subjects with Asthma on Short-Acting Beta2-Agonist Therapy Study Listed on ClinicalStudyDataRequest.com
SAS30018 Completed Comparison of stepwise treatment of asthmatic children with Salmeterol/Fluticasone propionate combination product (Seretide®) and/or Fluticasone propionate (Flixotide®) based on PD20 methacholine and symptoms or based on symptoms only (Children Asthma Therapy Optimal)

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.